Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis

Journal of the European Academy of Dermatology and Venereology

Volumn 28, Issue 2, 2014, Pages 192-203

  Mamolo, C ^a   Harness, J ^a,b   Tan, H ^a   Menter, A ^c  

^a PFIZER INC   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c BAYLOR RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TOFACITINIB; JANUS KINASE 3; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; ARTICLE; CONTROLLED STUDY; DERMATOLOGY LIFE QUALITY INDEX; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; ITCH SEVERITY SCORE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PAIN DISCOMFORT ASSESSMENT; PATIENT GLOBAL ASSESSMENT OF PSORIASIS; PATIENT SATISFACTION; PATIENT SATISFACTION WITH STUDY MEDICATION ITEM; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SHORT FORM 36; SKIN DISCOMFORT; SKIN PAIN; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; MIDDLE AGED; PSORIASIS; SEVERITY OF ILLNESS INDEX;

ADULT; DOUBLE-BLIND METHOD; FEMALE; HUMANS; JANUS KINASE 3; MALE; MIDDLE AGED; PATIENT OUTCOME ASSESSMENT; PATIENT SATISFACTION; PIPERIDINES; PROTEIN KINASE INHIBITORS; PSORIASIS; PYRIMIDINES; PYRROLES; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX;

EID: 84892605793     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.12081     Document Type: Article

References (30)

1. Tzu J, Krulig E, Cardenas V, Kerdel FA., Biological agents in the treatment of psoriasis. G Ital Dermatol Venereol 2008; 143: 315-327.
2. Menter A, Korman NJ, Elmets CA, et al,. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009; 61: 451-485.
3. Dubertret L, Mrowietz U, Ranki A, et al,. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol 2006; 155: 729-736.
4. Gottlieb AB, Dann F, Menter A,. Psoriasis and the metabolic syndrome. J Drugs Dermatol 2008; 7: 563-572.
5. Cohen AD, Dreiher J, Shapiro Y, et al,. Psoriasis and diabetes: a population-based cross-sectional study. J Eur Acad Dermatol Venereol 2008; 22: 585-589.
6. Sampogna F, Gisondi P, Melchi CF, Amerio P, Girolomoni G, Abeni D., Prevalence of symptoms experienced by patients with different clinical types of psoriasis. Br J Dermatol 2004; 151: 594-599.
7. Verhoeven EW, Kraaimaat FW, van de Kerkhof PC, et al,. Prevalence of physical symptoms of itch, pain and fatigue in patients with skin diseases in general practice. Br J Dermatol 2007; 156: 1346-1349.
8. National Psoriasis Foundation. National Psoriasis Foundation: report on the psycho-social impacts of psoriasis. 2009. Available at: http://www. psoriasis.org/NetCommunity/Document.Doc?id=619 (last accessed 18 November 2010).
9. Chosidow O, Dellavalle R, Do D, et al,. The Risk of Depression, Anxiety, and Suicidality in Patients With Psoriasis. Arch Dermatol 2010; 146: 891-895.
10. Richards HL, Fortune DG, Griffiths CE, Main CJ,. The contribution of perceptions of stigmatisation to disability in patients with psoriasis. J Psychosom Res 2001; 50: 11-15.
11. Fortune DG, Main CJ, O'Sullivan TM, Griffiths CE,. Quality of life in patients with psoriasis: the contribution of clinical variables and psoriasis-specific stress. Br J Dermatol 1997; 137: 755-760.
12. Mukhtar R, Choi J, Koo JY,. Quality-of-life issues in psoriasis. Dermatol Clin 2004; 22: 389-395. viii.
13. Rapp SR, Feldman SR, Exum ML, Fleischer AB, Reboussin DM,. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41: 401-407.
14. Menter A, Gottlieb A, Feldman SR, et al,. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008; 58: 826-850.
15. Horn EJ, Fox KM, Patel V, Chiou C-F, Dann F, Lebwohl M,. Are patients with psoriasis undertreated? Results of National Psoriasis Foundation survey. J Am Acad Dermatol 2007; 57: 957-962.
16. Chang BY, Zhao F, He X, et al,. JAK3 inhibition significantly attenuates psoriasiform skin inflammation in CD18 mutant PL/J mice. J Immunol 2009; 183: 2183-2192.
17. Coombs JH, Bloom BJ, Breedveld FC, et al,. Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2010; 69: 413-416.
18. Kremer JM, Bloom BJ, Breedveld FC, et al,. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dose levels of CP-690,550 versus placebo. Arthritis Rheum 2009; 60: 1895-1905.
19. Busque S, Leventhal J, Brennan DC, et al,. Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in de novo kidney allograft recipients. Am J Transplant 2009; 9: 1936-1945.
20. Boy MG, Wang C, Wilkinson BE, et al,. Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis. J Invest Dermatol 2009; 129: 2299-2302.
21. Papp K, Menter A, Strober B, et al,. Efficacy and safety of tofacitinib, an oral JAK inhibitor, in the treatment of psoriasis: a Phase 2b randomised placebo-controlled dose-ranging study. Br J Dermatol 2012; 167: 668-677.
22. Bronsard V, Paul C, Prey S, et al,. What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature. J Eur Acad Dermatol Venereol 2010; 24 (Suppl 2): 17-22.
23. Reich K, Segaert S, van de Kerkhof P, et al,. Once-weekly administration of etanercept 50 mg improves patient-reported outcomes in patients with moderate-to-severe plaque psoriasis. Dermatology 2009; 219: 239-249.
24. Torii H, Nakagawa H,. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial. J Dermatol Sci 2010; 59: 40-49.
25. Mazzotti E, Picardi A, Sampogna F, et al,. Sensitivity of the Dermatology Life Quality Index to clinical change in patients with psoriasis. Br J Dermatol 2003; 149: 318-322.
26. Hongbo Y, Thomas CL, Harrison MA, Salek MS, Finlay AY,. Translating the science of quality of life into practice: what do dermatology life quality index scores mean? J Invest Dermatol 2005; 125: 659-664.
27. Farhi D,. Ustekinumab for the treatment of psoriasis: review of three multicenter clinical trials. Drugs Today (Barc) 2010; 46: 259-264.
28. Gladman DD, Sampalis JS, Illouz O, Guerette B,. Responses to adalimumab in patients with active psoriatic arthritis who have not adequately responded to prior therapy: effectiveness and safety results from an open-label study. J Rheumatol 2010; 37: 1898-1906.
29. Swanbeck G, Inerot A, Martinsson T, et al,. Age at onset and different types of psoriasis. Br J Dermatol 1995; 133: 768-773.
30. Sato R, Milligan G, Molta C, Singh A,. Health-related quality of life and healthcare resource use in European patients with plaque psoriasis: an association independent of observed disease severity. Clin Exp Dermatol 2011; 36: 24-28.